
Investor Relations



CuraGen Corporation (ticker: CFGN) exchange: NASDAQ) Note: Release - 4-Mar-2003 A MARKET I MAY A MARKET OF AN ARTHUR AND A MARKET OF A

CuraGen Receives FDA Approval to Initiate Clinical Trials

V 5.2 181 to be a second

Potential Oral Mucositis Treatment Marks Successful Transition into Drug Development

NEW -54VER Conn., Mar 4 - 007 /PR Newsware-First Calib. 10. 10/43 ERC -- CuraGen Corporation (Nasdag, CPGN), a genomics-based pharmageutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigations: New Drug (1900) application to initiate canalal trials for CGS3135, a potential protein therapeutic being investigated as a treatment for oral mucositis. Oral mucositis is a side effect of chemotherapy and radiotherap, that results in the degradation or mucosal tissue that can range from redness and irritation to severe ulcerations of the mouth and throat. CaraGen now plans to proceed with a most center Phase I clinical trial to evaluate safety and pharmacokinetics in patients with concer who are at risk for inucositis following chemitterapy.

 ${\it muccesh}_{ij}$, a debintating complication of cancer chemotherapy or midiotherapy that affects the mice a tissue, which acts as a protective limit griving in the digestive track, inclinaing the mouth and threat. Symptoms range from partiand discomfort to severe uncerations that armit a patient's ability to ingest nutrients, plucositis can result in a suppressed immorane system that can reduce a patient's ability to tolerate further cancer therapy. The ayed treatment can lessen the effectiveness of the chemotherapy or radiotherapy, adversely impacting the value of the patient obverall treatment regimen.

 $^\circ \text{CG}53135 \otimes a$ novel protein discovered through the application of GuraGen's functional genomic technologies. In prestinical studies, this potential protein therapeutic reduced tissue inflammation and degeneration, and minimized the severity and extent of mucosal tissue damage. Mucositis is a significant unmet medical need, and we are pleased to have the apportunity to advance this promising molecule into human choical trials," stated Timothy Nr. Shannon, M.D., perior Vice President of R&D and Chief Medical Officer of CaraGen Corporation.

"Through the films of this II. a. CaraGen har become one of the first accommics companies to successful, transition from a target discovery company into a concords based pharmaceutical company. It is molecule represent, the trial of many promising candidates that we believe will emerge from our portishe of discovery and preclinical stage projects. We are pleased with the progress of this potential therape, to and look forward to ad bt one thitune successes. Intaked Johathan M. Mothberd on L. Fold dem Chairman, and CEO of Caracogn Corporation.

About CuraGen

 urafiles comparation (NASUAC) (PGN) is a genomics-parec pharmaceutical company. ParaGenesis stearated functions, denomic technologies and interret bread broinformatic systems are designed to geomate comprehensive aformation about golds, human genetic variations, done expression, protein interactions, portion pathways, and potential artids that affect these pathways. The Company is applying the adostrimized genomic technologies, informatics, and validation technologies to develop professiontibody, and small more the therapeutics to treat obesity and diabetes, sactor, inflan matery diseases, and central hervous systems. CNS1 delorders, Curación el codigia tercil o New Haven, CT and additional information is available at www.curagen.com

This press relinase may contain torward-locking statements including statements about $\mathcal{C}35 \times I/3 \times 2$ inconstrated CDM to be direct sold introduction and decimenation, and minimise to issue ity and extent of muces a tissue damage in precimee studies, as well united a senting the trist of many promising candidates that we believe will emerge from fur pertition of and were and profitted stage profests, but o statements are based on manageraem situs eat éispeillations and ané subject to a nun beil éitacturs and accontainties that could cau in advalinesuits to dithin materially from those described in the wirelands of the statements. CaraGen routions investors that the court be no assurance that actual results of business conditions will not differ materially from those projected of suggested in soon forward-looking statements as a result of various factors, including, but not limited to line following: CuraGen's expectation that it will incur laperating lasses in the near future, the early stage of development of CaruGen's products una technoliegies, arcentambles rélated to precimi ai una element testino and trials, runcerrainties and adverse results relating to Cura Sen's actify to notain ingulatory. approver for its products in coverapment, uncertainties summed and the availability of ladactions, trinding, "TuraCenis religings" on research collaborations indiscretegic alliances, the details of a nipetities of a device pine of a superficient employed a continued condition's ability to proceed to paterits and propertary rights, patent intro- in actions and uncertainties relating to communicativation in guts. Please refer to our Anough Report on Form 10 K for tar trico, violtiended December, M. 2001 for a description of these risks. We disclaim any interiorni o le praution ta upcata ce revisa any forward-source starements, whether as a result of new information, fature events, or otherwise.

SOURCE CuroGen Corporation

1 Homes.